ICU腹膜炎肠球菌之谜:一项多中心队列研究
这项回顾性多中心队列研究纳入法国西部四家医院ICU在2020至2022年间连续收治的392例腹膜炎成人患者,比较肠球菌分离与否的结局,并在肠球菌阳性者中比较早期(<48小时)启用活性抗肠球菌治疗与否的90天生存。肠球菌分离率为41.1%(161/392),肠球菌阳性与阴性患者ICU死亡率分别为29.8%与28.1%(p=0.805),无显著差异。多变量分析显示术后腹膜炎、弥漫性腹膜炎和实体器官移植与肠球菌分离独立相关。在155例有治疗数据的肠球菌腹膜炎患者中,95例(61%)接受早期活性治疗,早期治疗与90天生存改善无显著关联(粗分析HR 0.71 [95%CI 0.39-1.27],p=0.241;加权Cox回归HR 0.66 [95%CI 0.37-1.18],p=0.160)。
要点
- ICU腹膜炎患者肠球菌分离率为41.1%(161/392),肠球菌阳性与阴性者ICU死亡率分别为29.8%与28.1%(p=0.805),无显著差异。
- 术后腹膜炎(aOR 2.56 [1.67-3.95],p<0.001)、弥漫性腹膜炎(aOR 1.78 [1.10-2.89],p=0.020)和实体器官移植(aOR 5.82 [1.18-28.76],p=0.031)与肠球菌分离独立相关。
- 在155例肠球菌腹膜炎患者中,61%(95例)接受早期(<48小时)活性抗肠球菌治疗,粗分析HR 0.71 [95%CI 0.39-1.27](p=0.241),加权Cox回归HR 0.66 [95%CI 0.37-1.18](p=0.160),均未达统计学显著。
- 肠球菌分离与更高死亡率无独立关联,早期针对性抗肠球菌治疗未显示统计学显著的结局改善。
适用人群与场景
- 2020至2022年法国西部四家医院ICU连续收治的成人腹膜炎患者。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究,纳入四家医院ICU的392例成人腹膜炎患者,比较肠球菌分离与否的结局,并在肠球菌阳性者中比较早期(<48小时)活性抗肠球菌治疗与否的90天生存。
- 肠球菌分离率41.1%(161/392);肠球菌阳性与阴性患者ICU死亡率分别为29.8%与28.1%(p=0.805)。
- 多变量分析:术后腹膜炎aOR 2.56 [1.67-3.95](p<0.001)、弥漫性腹膜炎aOR 1.78 [1.10-2.89](p=0.020)、实体器官移植aOR 5.82 [1.18-28.76](p=0.031)与肠球菌分离独立相关。
- 在155例有治疗数据的肠球菌腹膜炎患者中,95例(61%)接受早期活性治疗;早期治疗与90天生存改善无显著关联:粗分析HR 0.71 [95%CI 0.39-1.27](p=0.241),加权Cox回归HR 0.66 [95%CI 0.37-1.18](p=0.160)。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 肠球菌分离在ICU腹膜炎中常见,但本研究显示其与更高死亡率无独立关联。
- 本研究显示早期(<48小时)针对性抗肠球菌治疗与90天生存改善无统计学显著关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The role of Enterococcus spp. and the need for specific anti-Enterococcus therapy in Intensive Care Unit (ICU) patients with peritonitis remain debated.
METHODS: We conducted a retrospective multicentre cohort study including all consecutive adults admitted to the ICUs of four hospitals in western France with peritonitis between 2020 and 2022. Outcomes were compared according to Enterococcus spp. isolation and, among Enterococcus-positive cases, according to early administration (< 48 h) of active antimicrobial therapy. Propensity-weighted Cox models were used to estimate 90-day survival.
RESULTS: Among 392 patients, Enterococcus spp. were isolated in 161 (41.1%). Enterococcus-positive patients were older and more frequently had postoperative and diffuse peritonitis. ICU mortality rates were 29.8% vs 28.1% in patients with and without Enterococcus infection (p = 0.805). In multivariable analysis, postoperative peritonitis (aOR 2.56 [1.67-3.95], p < 0.001), diffuse peritonitis (aOR 1.78 [1.10-2.89], p = 0.020) and solid organ transplantation (aOR 5.82 [1.18-28.76]; p = 0.031) were independently associated with Enterococcus isolation. Among the 155 patients with documented Enterococcus peritonitis and available antimicrobial treatment data, 95 (61%) received early active therapy. Early anti-Enterococcus treatment was not associated with improved 90-day survival either in the raw population (HR 0.71 [95% CI 0.39-1.27]; p = 0.241) or after weighted Cox regression (HR 0.66 [95% CI 0.37-1.18]; p = 0.160).
CONCLUSIONS: Enterococcus spp. isolation appears common in ICU peritonitis but not independently associated with higher mortality. Early targeted antimicrobial therapy was not associated with a statistically significant improvement in outcomes.
参考来源
- Bardoul M, Angebault C, Fillâtre P, et al. Unraveling the Enterococcus enigma in ICU peritonitis: a multicenter cohort study. Crit Care. 2026. PMID: 41731517. doi:10.1186/s13054-026-05867-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。